Clinical Trial Update: Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study evaluating sirolimus in autosomal dominant polycystic kidney disease with severe renal insufficiency has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2, Phase 3 | Status: TERMINATED